OTC : GENSF
$0 (0.0%)
OTC
Jorgen Kokke
Biotechnology
Healthcare
GENSF
3500
GB
USD
0.52
2.25
1.70
0.32
0.44
$672.8M
2.11
2.80
24.80
0.87
$0.25
$19.3M
7.07%
9.63%
9.70%
5.16%
29.67
0.02
0.02
3/5
0 Analysts
%
4.58
7/9
$169.07M
$921.15M
$417.33M
$98.69M
$1.64B
2.44
14.28
2.25
9.70%
6.05%
3.36%
4.02%
$11.11
514 days
| Name | Title |
|---|---|
| Angelle R. Rosata | Chief Human Resources Officer |
| Andrew Paul Russell | Chief Financial Officer & Executive Director |
| Jim Low | Chief Operating Officer of Genus ABS |
| Jorgen Kokke | Chief Executive Officer & Executive Director |
| Janet Duane | Group Financial Controller |
| Lucie Mary Katja Grant | Group General Counsel & Company Secretary |
| Matt Culbertson | Chief Operating Officer |
| Mark Birri | Chief Corporate Development Officer |
| Elena Rice | Head of R&D and Chief Scientific Officer |
No votes yet today — be the first to share your view!
About Genus plc (OTC:GENSF) Stock
Genus plc is a global animal genetics company, with operations extending across North America, Latin America, the United Kingdom, broader Europe, the Middle East, Russia, Africa, and Asia. The firm organizes its business into three primary segments: Genus PIC, Genus ABS, and Genus Research and Development. Through its PIC brand, the company supplies breeding pigs and boar semen, enabling the production of swine with specific traits for pork processing. Furthermore, under the ABS, Genus, and Bovec labels, it provides bull semen and bovine embryos to facilitate the breeding of calves with targeted characteristics for dairy and beef output. Genus plc also extends specialized technical support to agricultural producers. Established in 1994, the company's headquarters are located in Basingstoke ... , United Kingdom.
Genus says its set to beat market expectations
2026-07-14 06:06:51
Genus PLC (LSE:GNS) said full-year profit is set to beat market expectations after stronger second-half trading and cash proceeds from its Chinese porcine joint venture strengthened the animal genetics group's balance sheet. Adjusted profit before tax for the year ended 30 June is expected to be approximately £98 million, ahead of the company-compiled consensus range of £94.3 million to £96.9 million.
Frequently Asked Questions
What is the current Genus plc (GENSF) stock price?
Genus plc(OTC:GENSF) stock price is $31.065 in the last trading session. During the trading session, GENSF stock reached the peak price of $37.25 while $26.01 was the lowest point it dropped to. The percentage change in GENSF stock occurred in the recent session was 0.0% while the dollar amount for the price change in GENSF stock was $0.
GENSF's industry and sector of operation?
The OTC listed GENSF is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of GENSF?
Angelle R. Rosata
| Chief Human Resources Officer
Andrew Paul Russell
| Chief Financial Officer & Executive Director
Jim Low
| Chief Operating Officer of Genus ABS
Jorgen Kokke
| Chief Executive Officer & Executive Director
Janet Duane
| Group Financial Controller
How many employees does GENSF have?
Number of GENSF employees currently stands at 3500. GENSF operates from Matrix House, Basingstoke, HM RG21 4DZ, GB.
Link for GENSF official website?
Official Website of GENSF is: https://www.genusplc.com
How do I contact GENSF?
GENSF could be contacted at phone #44 1256 347 100 and can also be accessed through its website. GENSF operates from Matrix House, Basingstoke, HM RG21 4DZ, GB.
How many shares of GENSF are traded daily?
The average number of GENSF shares traded daily for last 3 months was 14.
What is the market cap of GENSF currently?
The market value of GENSF currently stands at $2.06B with its latest stock price at $31.065